Abstract. The role of SGLT2 (the gene for a renal sodiumdependent glucose transporter) in renal glucosuria was evaluated. Therefore, its genomic sequence and its intron-exon organization were determined, and 23 families with index cases were analyzed for mutations. In 21 families, 21 different SGLT2 mutations were detected. Most of them were private; only a splice mutation was found in 5 families of different ethnic backgrounds, and a 12-bp deletion was found in two German families. Fourteen individuals (including the original patient with 'renal glucosuria type 0') were homozygous or compound heterozygous for an SGLT2 mutation resulting in glucosuria in the range of 14. 
The molecular bases of three congenital defects of cellular glucose transport, affecting either facilitative ("passive") or sodium-dependent ("active") transport, have been elucidated in recent years (1) (2) (3) . In addition, a defect of the renal lowaffinity sodium/glucose cotransporter SGLT2 gene (also referred to as SLC5A2, [OMIM 182381]) has long been proposed to cause renal glucosuria (OMIM 233100) (4) .
Renal glucosuria is a "nondisease"; the great majority of affected individuals do not have any complaints, and only very rarely a propensity to hypovolemia and hypoglycemia has been described. Renal glucosuria is defined by urinary glucose excretion in the presence of a normal blood glucose concentration and the absence of any signs of a general renal tubular dysfunction. Renal glucosuria may vary from few grams to Ͼ100 g (556 mmol) per day. Mild glucosuria has been known for decades; it is relatively common and often inherited as an autosomal dominant trait (5) . Severe glucosuria is rare, and the first patient with virtual absence of tubular glucose reabsorption, termed renal glucosuria type 0, was not reported until 1987. The pedigree of this patient's family suggested autosomal recessive inheritance (6) .
The purpose of this study was to define the molecular basis of renal glucosuria. Therefore, we first characterized the genomic structure of the human SGLT2 gene, which we reported to GenBank in 2000 (accession no. AF307340). We then performed mutation analysis in patients with isolated, massive glucosuria. It turned out that homozygosity or compound heterozygosity for SGLT2 mutations may account for this condition, which was reported in abstract form in the same year (7) . On the basis of these reports, a single patient with glucosuria and homozygosity for an SGLT2 mutation has meanwhile been published (8). Here, we summarize our results of the characterization of the SGLT2 gene and present our data on 23 consecutive families with index patients with renal glucosuria, including the original patient with renal glucosuria type 0.
Materials and Methods

Subjects
Ninety-three individuals from 23 unrelated families with at least one index patient with renal glucosuria were investigated. In general, urinary glucose concentration had been repeatedly determined by dipstick before it was quantified by the glucose oxidase method in aliquots of 24-h urine collected on a free diet. It ranged from a minimal elevation of Ͻ1 g/ (9)). None of these subjects had any signs of a generalized tubular dysfunction or of any other type of renal disease. The families originated from Germany, Switzerland, England, Italy, former Yugoslavia, Turkey, and Pakistan. Patient 01-1 was originally described by Oemar et al. (6) in 1987 in the first report of an individual with virtually absent renal glucose reabsorption (renal glucosuria type 0). This individual, now 32 yr old, has had entirely normal renal function parameters so far; a detailed follow-up report of this case is currently in preparation.
Molecular Genetic Studies
High molecular genomic DNA was prepared from leukocytes from individuals with renal glucosuria and their parents and siblings and control subjects according to standard protocols (10) . Determination of the genomic sequence of human SGLT2 was accomplished by primer walking starting from a previously reported human SGLT2 cDNA (11) with the assumption of similar intron-exon boundaries when compared with the genomic structure of SGLT1, the homologous glucose transporter of intestinal cells (12) . The 5'-untranslated region of SGLT2 was determined by a two-step PCR technique using random primers according to the manufacturer's instructions (Dynal A.S, Nordic, Oslo, Norway). The primer pair (with the annealing temperature given in parentheses) used for the first step was sn 5'-CAGTTCAAGCTTGTCCAGGAATTCNNNNNNNGGCCT-3' and asn (biotin)-5'-GGTTTCTCCTTCAAAGATCCAA-3' (62°C); the one for the second step was sn (biotin)-5'-CAGTTCAAGCTT-GTCCAGGAATTC-3' and asn 5'-CCAGCAGCCACCAGCAG-CACA -3' (62°C).
For mutation analysis in renal glucosuria families, the entire coding region and adjacent intronic segments were sequenced in as many family members as possible. PCR products including exons 1 to 14 of SGLT2 with flanking intron sequences were generated on the basis of the newly determined intronic sequences. Primer pairs used in this study are given in Table 2 . PCR was carried out in a T3 Thermocycler (Biometra, Göttingen, Germany) with reagents and Taq polymerase (Invitrogen, Karlsruhe, Germany). Double-stranded PCR products were analyzed by nondenaturing PAGE combined with silver and ethidium bromide staining, respectively. Purified samples were then analyzed by direct cycle sequencing of double-stranded DNA according to the protocol for 33 P-labeled terminators provided with the Thermo Sequenase cycle sequencing kit (Amersham Buchler, Freiburg, Germany). When necessary, sequencing was performed after cloning the respective PCR product into a phagemid vector according to the PCR Script Amp Cloning kit (Stratagene, Heidelberg, Germany). All detected mutations were confirmed by restriction enzyme digest (in some cases, after the use of a mismatch primer) and/or detection of heteroduplex formation on a polyacrylamide gel. Nucleotides of the human SGLT2 cDNA are numbered from 1 to 2019 for the first bp of the ATG initiation codon and the last bp of the TAA stop codon; amino acids are numbered from 1 to 672 for methionine and alanine, respectively.
Results
Genomic Organization of the Human SGLT2 Gene
As a first result, our studies confirmed that the human SGLT2 coding sequence consists of 2019 bp predicting a 672-amino acid protein. This human renal glucose carrier shows 58% amino acid identity on Clustal W multiple sequence alignment (clustalw.genome.ad.jp) with the SGLT1 protein and the degree of homology is even higher in central domains of the polypeptide. Analysis of the genomic structure of human SGLT2 revealed an 8.0-kb gene with an intron-exon organization that also shows high similarity to SGLT1 ( Figure  1 ). The coding sequence of SGLT2, however, is interrupted by only 13 introns that, with one exception, are located at homologous positions in SGLT1. Intron sizes in general are remarkably smaller in SGLT2 and at the position of intron 4 of SGLT1, an intron is absent in SGLT2. All 13 introns of SGLT2 show the consensus sequence ag...gt. A highly polymorphic marker that has not previously been described in the literature with a variable number of CA repeats is present in intron 1 of SGLT2.
Mutation Analysis in Patients with Renal Glucosuria
The degree of urinary glucose excretion and the results of SGLT2 mutation analysis for individual family members who participated in this study are presented in Table 1 . With the exception of two families (14 and 19) , SGLT2 mutations were detected in all families investigated. The 14 individuals who were found to be carriers of two mutated alleles (boldface in Table 1 ) showed "severe" glucosuria, here defined by a cutoff of urinary glucose of Ͼ10 g/1.73 m 2 per d (55 mmol/1.73 m 2 per d). Among them is the patient in whom glucosuria type 0 was originally described. He was found to be homozygous for a 5-bp deletion within exon 8 of the SGLT2 gene ( Figure 2 ). As expected, family members of these cases of severe glucosuria were shown to be heterozygous carriers of SGLT2 mutations. Investigations for glucose excretion showed that some but not all of them had glucosuria in a range of up to 4. The study detected a total of 21 different SGLT2 mutations, which are summarized in Table 3 . Nonsense mutations, missense mutations, and small deletions were scattered over the SGLT2 coding sequence. Most of them were confined to a single pedigree. Only the ⌬385-8 mutation was found in two unrelated German patients, and five individuals who originated from Pakistan, former Yugoslavia, Italy, and Switzerland carried the same intron 7 donor splice site mutation.
Discussion
The studies reported here led to the description of SGLT2 mutations in patients with isolated renal glucosuria (7). As a first step, we characterized the human SGLT2 gene at the genomic level. We assumed that SGLT2, which has previously been reported to be located in the chromosomal region 16 (13) , not only has a high sequence similarity to the best characterized member of the SGLT family, human SGLT1, but also shows a high degree of similarity regarding its structural organization. We could demonstrate that most of the SGLT1 intron-exon boundaries are located at corresponding positions in SGLT2 (Figure 1 ). On the basis of these results and a primer walking technique, it was easy to determine the genomic sequence of SGLT2, which we reported to GenBank in 2000 (accession no. AF307340).
One difference between SGLT1 and SGLT2 is noteworthy: The absence of an intron at the position of intron 4 in SGLT1. This is an interesting finding in regard to the structural organization of two novel members of the SGLT family that have recently been reported. In one of them, SGLT3, the gene for another renal low-affinity glucose transporter with 659 amino acids that, like SGLT1, is located on chromosome 22 and probably is the product of an ancient gene duplication; this intron is present (14,15) . In contrast, in SGLT4, a novel mem- ber that predicts a protein of 674 amino acids and that has been detected during systematic sequencing of the chromosomal region 1p32.1 to 33, an intron is missing at this position (15, 16) . Thus, both SGLT2 and SGLT4 have only 14 exons and 13 introns with a very similar intron-exon structure, and, possibly, SGLT2 is more closely related to this gene than to SGLT1. Not surprising, SGLT1 and SGLT3 have the highest alignment score (69%); for comparison, the score for SGLT2 is 53% when aligned to SGLT4 and 58% when aligned to SGLT1. SGLT1 and SGLT3 have the same sodium-to-sugar stoichiometry (2:1) (17), whereas there is a hint that sodium-glucose coupling in SGLT2 is 1:1 (4,11,18). It will be interesting to know these and other transport properties for SGLT4. With the knowledge of the genomic structure and sequence of human SGLT2, we were able to screen patients with isolated renal glucosuria for SGLT2 mutations. That we detected SGLT2 mutations in 21 of 23 consecutively investigated families clearly shows the importance of the SGLT2 protein in renal tubular glucose reabsorption. After some ambiguity about the identity of the major renal sodium-glucose co-transporter, our results are in line with the accepted dogma that the bulk of filtered glucose is reabsorbed in segments S1 and S2 of the proximal convoluted tube by the low-affinity, high-capacity carrier SGLT2 (15) . They further demonstrate that other sodium-dependent transporters cannot be upregulated to compensate for a nonfunctional SGLT2 protein.
All cases with SGLT2 mutations on both chromosomes showed "severe" glucosuria; none of these individuals had a glucose excretion Ͻ10 g/1.73 m 2 per d (55 mmol/1.73 m 2 per d). The well-documented case of glucosuria type 0 (patient 01-1 in Table 1 (6)) with a daily glucose excretion in excess of 100 g/1.73 m 2 per d demonstrates that a truncating mutation on both chromosomes may result in virtual absence of glucose reabsorption. If transferred to the brush border membrane at all, then the protein predicted by this mutation would have only the seven N-terminally located transmembranous domains, whereas domains 8 to 14 would be missing. Such a mutation has been shown to result in a nonfunctional glucose transporter because it lacks the transmembranous domains 10 to 13 that have been demonstrated to be essential for sugar binding and sugar translocation (15, 19, 20) . It is interesting, however, that one patient (patient 06-1) homozygous for a truncating mutation showed a considerably lower glucose excretion, suggesting some glucose reabsorption by an unknown alternative mechanism.
Cases of "severe" glucosuria show the characteristics of autosomal recessive inheritance. The parents were consanguineous in a significant proportion of the families (seven of 12), suggesting that SGLT2 mutations are rare in the populations from which our cases originated. Some of these cases had homozygous or compound heterozygous mutations that might have resulted in some residual activity of the transporter: patients with two mutated alleles and glucosuria in the range of 10 to 50 g/1.73 m 2 per d (55 to 280 mmol/1.73 m 2 per d) carried at least one mutation that could explain some residual activity (Table 1) , i.e., these patients carried at least one missense or a splice site mutation. An example is the relatively common SGLT2 IVS7 ϩ5 gϾa mutation, a donor splice site mutation that was found to be associated with some residual glucose reabsorption and comparably low glucose excretion. It is well known that this type of mutation results in both abnormally and normally spliced mRNA with the effect of a decreased amount of the gene product with normal kinetic properties (21) (22) (23) .
Among the patients with "mild" glucosuria, here defined by a glucose excretion Ͻ10 g/1.73 m 2 per d (55 mmol/1.73 m 2 per d), SGLT2 mutations, if present at all, were found in the heterozygous state. However, not in all individuals heterozygous for a specific mutation was an increased glucose excretion observed, and even among family members with identical SGLT2 mutations, only some had mild glucosuria. This suggests that other genetic or nongenetic factors have to be present before heterozygosity for an SGLT2 mutation results in mild glucosuria. Therefore, inheritance of renal glucosuria can best be described to follow a codominant trait with variable penetrance.
These results of our molecular genetic study are in accordance with earlier clinical observations. Before quantification of glucose excretion in urine became a clinical routine, renal glucosuria was generally considered to follow a dominant trait (5) . Further studies have shown that mild glucosuria is relatively frequent and that cases of "heavy glucosuria" are extremely rare (9, 24) . Furthermore, it has already been reported that parents of patients with severe glucosuria may or may not show an abnormality of renal glucose transport (9).
Our results also provide an explanation for titration studies performed in the 1950s defining the classical types of renal glucosuria (25, 26) . A diminished amount of the normal SGLT2 protein should result in type A glucosuria, characterized by a lowered renal transport maximum for glucose (T m G). However, patients with certain SGLT2 missense mutations resulting in a diminished affinity of the transporter for its substrate may belong to type B for which a normal T m G and an exaggerated splay is characteristic. T m G and renal threshold for glucose will have to be determined for patients characterized at the molecular genetic level to determine whether these assumptions are correct. Compound heterozygosity for SGLT2 mutations, however, is probably the reason that many cases of severe glucos- uria could not be clearly classified into type A or B in the past and that a broad spectrum of impairment of tubular glucose transport has been found in such patients (27) .
Heterozygosity for an SGLT2 mutation can result in mild glucosuria, and both nonsense and missense mutations may have this effect. It is interesting that this is in contrast to recent observations in individuals heterozygous for a mutation of GLUT2, the gene of the basolateral glucose carrier of tubular cells. Whereas GLUT2 missense mutations were associated with mild glucosuria, nonsense mutations were reported not to result in an increased glucose excretion (28) . This was explained by a dominant negative effect of the missense mutation on the GLUT2 hexamer. Such an effect might not play a role in sodium-dependent transporters because freeze-fracture electron microscopic studies have suggested that they function as monomers (29) .
The 21 SGLT2 mutations detected during the course of this study are summarized in Table 3 . All of the nonsense and frameshift mutations predict proteins that lack the previously mentioned transmembranous domains 10 to 13 essential for sugar binding and sugar transport of SGLT proteins. Many of the missense mutations (T51P, R137H, G272R, K311R, and R499C) affect residues that are highly conserved across the human SGLT family and across SGLT of other species (Mus musculus [mouse], Rattus norvegicus [rat], Oryctolagus cuniculus [rabbit]), which underlines their pathogenic role. Other missense mutations (G449D and F453L) lie in very close vicinity to Q457, the residue interacting with O1 and O5 of the pyranose in SGLT1 (30) . SGLT2 mutations seem to be randomly distributed along the coding sequence of the gene, but, interestingly, no SGLT2 mutation was detected in regions 289 to 304 and 369 to 405, 1 considered to be mutational hot spots in SGLT1 (31) . The only locations where naturally occurring mutations have been observed both in SGLT1 and SGLT2 are R137 and R499. 2 A patient with glucose-galactose malabsorption and compound heterozygosity for SGLT1 R499H (together with R379X) was severely affected clinically, and the functional expression of this mutant in oocytes has been shown to result in a significant decrease of sugar affinity and trafficking to the membrane. It has been reported, however, that replacing this residue by cysteine restored trafficking and resulted in a functional sugar transporter (32) . This stands in contradiction a fs. . ., frameshift mutation described by the last regular amino acid before the frameshift and the position of the predicted premature termination (X) of translation of the SGLT2 protein.
b mm denotes the use of a mismatch primer for DNA amplification (sequences available upon request), (ϩ) stands for the gain and (Ϫ) for the loss of a restriction site for the given enzyme in the presence of the mutation. HD; heteroduplex formation on PAGE.
c Family numbers refer to Table 2 Numbers in boldface symbolize homozygosity; numbers in standard style symbolize heterozygosity for a given mutation.
d In addition to this Turkish family, the same mutation was detected in another Turkish family reported by van den Heuvel et al. (8); glucose excretion of the other case was 61.6 g/L; parents and sibilings were reported not to have glucosuria.
to our observation of an individual with compound heterozygosity for SGLT2 R499C (together with Y150H) and significant renal glucosuria, which cannot be solely explained by the other mutated allele (see patients 20-1 and 20-3, Table 1 ).
How SGLT2 missense mutations result in an impairment of glucose transport is still unclear. However, as a result of the great sequence and structure homology of SGLT, it is tempting to suppose that disturbed trafficking shown to play a major role for SGLT1 mutations also is an important factor in SGLT2 (31) . Unequivocally, it is a drawback of our study that we were not able to express SGLT2 mutants in heterologous expression systems to investigate the effect of mutations in comparison with the wild-type glucose carrier. Although we spent particular efforts in expression studies both in Xenopus laevis oocytes and in isolated vesicles, techniques that have worked perfectly in our hands when expressing SGLT1 and other transporters (33,34), we were not successful expressing SGLT2 (data not shown). However, it has previously been noticed that human SGLT2, unlike SGLT1 and SGLT3, expresses very poorly in oocytes and COS-7 cells (15, 35) . The sodium-dependent uptake of sugar and the sodium-sugar currents in SGLT2 oocytes were, at most, 3.5 times greater than those in controls (4), whereas expression of SGLT1 or SGLT3 in oocytes resulted in sugar fluxes and currents up to 2000 times greater than controls. Whether additional posttranslational modification is required before SGLT2 expresses in oocytes is uncertain. An important role of protein kinases for sodium-glucose co-transporters has been demonstrated for SGLT1, and it has been suggested that despite that SGLT show high sequence homology, minor differences in amino acid sequence may dramatically change the regulation of trafficking by protein kinases (36) . The ultimate reason for poor expression of SGLT2 in heterologous systems, however, has remained unclear.
Two of our index patients with renal glucosuria (patients 14-1 and 19-1 in Table 1 ) did not have any detectable SGLT2 mutation, and in one of the cases with relatively severe glucosuria, we would have expected to find a second SGLT2 mutation (patient 07-1). This can of course be the result of technical problems. Some SGLT2 mutations may not be detectable with the PCR-based technique applied in this study, and SGLT2 mutations outside the coding region, e.g., within the promotor region, would have escaped our analysis. In that context, it is interesting that the transcription of mouse SGLT2 is regulated by hepatic nuclear factor (HNF)-1␣ (37) , and, at least for human SGLT1, the binding domain for this transcription factor has recently been characterized (38) . Only limited information on transcriptional regulation is available for human SGLT2.
Despite the important role of SGLT2, other genes may be involved in renal glucose transport to varying degrees and may be mutated in patients with renal glucosuria. Intestinal glucosegalactose malabsorption, a congenital defect of SGLT1, is well known to be accompanied by glucosuria, but there were no intestinal symptoms in our patients. Other members of the SGLT family (SGLT3, SGLT4, and SMIT2), however, are candidates that should be investigated. Furthermore, a defect of HNF-1␣, known to cause maturity-onset diabetes in the young type 3, has been reported to be accompanied by a diminished renal threshold for glucose. Such a defect is unlikely in our patients because other signs of maturity-onset diabetes in the young were absent. The possibility of a heterozygous GLUT2 missense mutation has been discussed above; therefore, we will have to investigate glucosuria patients for GLUT2 mutations even though we have not observed glucosuria in patients heterozygous for a GLUT2 missense mutation (unpublished data). Finally, mutations in other genes, such as a hypothetical locus termed GLYS1 detected by linkage studies on chromosome 6 (39) , cannot be ruled out. However, because both of our index patients without an SGLT2 mutation showed only mild to moderate glucosuria, this does not challenge the major result of our study. The detection of SGLT2 mutations in all patients with severe renal glucosuria and that virtual absence of glucose reabsorption in some of the patients was associated with a mutation predicting a nonfunctioning SGLT2 protein are evidence that SGLT2 plays a very important role in renal tubular glucose transport.
